Please assess the completion status of the following clinical trial:

Trial Title: Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Key Inclusion Criteria:~* HIV-1 infection~* Aged ≥ 18 years at Pre-baseline/Day -13~* On antiretroviral (ARV) treatment for ≥ 12 consecutive months prior to Pre-Baseline/Day -13~  * The following agents are allowed as part of the current ARV regimen: NRTIs, raltegravir, dolutegravir, rilpivirine, and maraviroc~ * The following agents are NOT allowed as part of the current ARV regimen: HIV protease inhibitors (including low dose ritonavir), cobicistat-containing regimens, elvitegravir, efavirenz, etravirine, and nevirapine~ * A change in ARV regimen ≥ 45 days prior to baseline/Day 1 for reasons other than virologic failure (eg, tolerability, simplification, drug-drug interaction profile) is allowed~* Plasma HIV-1 RNA \< 50 copies/mL at screening~* Documented plasma HIV-1 RNA levels \< 50 copies/mL (according to the local assay being used) for ≥ 12 months preceding the screening visit (measured at least twice using a licensed assay with a lower limit of quantitation of at least 40 copies/mL)~  * Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or blip) prior to screening are acceptable. (If the lower limit of detection of the local HIV-1 RNA assay is \< 50 copies/mL, the plasma HIV-1 RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests)~ * If ART regimen is changed ≥ 60 days prior to Pre-Baseline/Day -13, plasma HIV-1 RNA \<50 copies/mL at Pre-baseline/Day -13 visit is required~* No documented history of resistance to any components of the current ARV regimen~* Availability of a fully active alternative ARV regimen, in the opinion of the Investigator, in the event of discontinuation of the current ARV regimen with development of resistance~* Hgb ≥ 11.5 g/dL (males) or ≥ 11 g/dL (females)~* White blood cells (WBC) ≥ 4,000 cells/μL~* Platelets ≥ 150,000/mL~* Absolute neutrophil count (ANC) ≥ 1500 cells/μL~* CD4 count ≥ 400 cells/μL~* Albumin ≥ 3.9 g/dL~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of the normal range (ULN)~* Estimated glomerular filtration rate ≥ 60 mL/min~* No autoimmune disease~Key Exclusion Criteria:~* Hepatitis B surface antigen (HBsAg) positive~  * Positive anti-HBs antibody and negative HBsAg results are acceptable~* Hepatitis C antibody (HCVAb) positive~  * Positive anti-HCV antibody and negative HCV polymerase chain reaction (PCR) results are acceptable~* Documented history of pre-ART CD4 nadir \< 200 cells/µL~  * Unknown pre-ART CD4 nadir is acceptable~* A new AIDS-defining condition diagnosed within 90 days prior to screening~* Acute febrile illness within 35 days prior to pre-baseline/Day -13~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vesatolimod 1 mg (Cohort 1) (Type: EXPERIMENTAL): Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
- Vesatolimod 2 mg (Cohort 2) (Type: EXPERIMENTAL): Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
- Vesatolimod 4 mg (Cohort 3) (Type: EXPERIMENTAL): Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
- Vesatolimod 6 mg (Cohort 4) (Type: EXPERIMENTAL): Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
- Vesatolimod 8 mg (Cohort 5) (Type: EXPERIMENTAL): Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
- Vesatolimod 10 or 12 mg (Cohort 6) (Type: EXPERIMENTAL): Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
- Vesatolimod 12 mg (Optional Cohort 7) (Type: EXPERIMENTAL): Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
- Vesatolimod 6 mg with an acidic solution (Optional Cohort 8) (Type: EXPERIMENTAL): Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
- Vesatolimod up to 12 mg (Cohort 9) (Type: EXPERIMENTAL): Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
- Placebo (Cohorts 1-9) (Type: PLACEBO_COMPARATOR): Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete